Microdosing (part 3): The path to FDA approval w/ MindMed and Diamond Therapeutics

Business Trip

English - August 16, 2022 16:00 - 58 minutes - 40.2 MB
Entrepreneurship Business Health & Fitness Mental Health psychedelics psychedelic psychedelic startups mental health wellness human flourishing Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Microdosing (part 2): Placebo is a hell of a drug with Balázs Szigeti

Next Episode: Soltara: an ethical and profitable ayahuasca retreat

This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications.

In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilocybin and is focused on anxiety disorders. Meanwhile, MindMed is focused using low doses of LSD to treat adult ADHD. Our guests are Dr. Michael McDonnell (Diamond Therapeutics) and Dr. Dan Karlin (MindMed).

In case you missed it: In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we discuss placebo effect and the results of a self-blinded placebo-controlled study with Balázs Szigeti from the Centre for Psychedelic Research at Imperial College London.

Disclaimer: This is not investment advice and is for information and educational purposes only.

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin and Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank

Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love

Additional Music:
Distant Daze by Zack Frank